Edaravone, a Free Radical Scavenger, can Effect on the Inflammatory Biomarkers in Acute Ischemic Stroke Patients
|Taizen Nakase*, Masahiro Sasaki and Akifumi Suzuki|
|Department of Stroke Science, Research Institute for Brain and Blood Vessels, Akita, Japan|
|Corresponding Author :||Taizen Nakase
Department of Stroke Science
Research Institute for Brain and Blood Vessels
6-10 Sensyu Kubota Machi, 010-0874, Akita, Japan
E-mail: [email protected]
|Received May 19, 2014; Accepted June 21, 2014; Published June 24, 2014|
|Citation: Nakase T, Sasaki M, Suzuki A (2014) Edaravone, a Free Radical Scavenger, can Effect on the Inflammatory Biomarkers in Acute Ischemic Stroke Patients. J Neurol Disord 2:167. doi: 10.4172/2329-6895.1000167|
|Copyright: © 2014 Nakase T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Background: This study was aimed to explore whether the free radical scavenger, edaravone, can reduce the inflammatory response providing better outcome along with not only conventional therapy but also recombinant tissue plasminogen activator (rt-PA) thrombolytic therapy.
Results: Acute ischemic stroke patients were enrolled (n=64, average 73.3 year-old) for measuring interleukin-6 (IL-6), tumor necrosis factor (TNFα) and malondialdehyde-modified LDL (MDA-LDL) as inflammatory biomarkers at 3 time points: before medication, 5 hrs and 24hs following medication. All patients were classified into four groups depending on the medication: conventional therapy without edaravone (n=15), conventional therapy with edaravone (n=34), rt-PA thrombolytic therapy without edaravone (n=4) and rt-PA thrombolytic therapy with edaravone (n=11). Neurological alteration was assessed by NIH Stroke Scale on admission and at 1 month. As the results, the inflammatory markers were reduced in the edaravone treated group, although it was not significant. While, IL-6 was significantly increased at 24 hrs in the thrombolytic group than the conventional group. Patients treated with rt-PA and edaravone exhibited better outcome than only rt-PA treated patients, although there was no difference of the recanalization rate.
Conclusion: Edaravone may be able to decrease the amplified inflammatory response following brain infarction, providing better outcome.